Thiazolidinediones and clinical outcomes in type 2 diabetes (Q45329033)

13 December 2017

title

Thiazolidinediones and clinical outcomes in type 2 diabetes (English)

1 reference

13 December 2017

0 references

2

Bernard Zinman

1 reference

13 December 2017

Ravi Retnakaran

1

1 reference

13 December 2017

language of work or name

English

0 references

publication date

6 June 2009

1 reference

13 December 2017

1 reference

13 December 2017

volume

373

1 reference

13 December 2017

issue

9681

1 reference

13 December 2017

page(s)

2088-2090

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

1 reference

7 January 2021

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Thiazolidinediones and Heart Failure: A teleo-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for th

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961029-1

7 January 2021

10.1016/S0140-6736(09)61029-1

Identifiers

DOI

1 reference

13 December 2017

1 reference